Can we predict dangerous blood clots in lung cancer immunotherapy patients?
NCT ID NCT06950697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how often lung cancer patients on immune checkpoint inhibitors develop blood clots (in veins or arteries) and what factors increase that risk. Researchers will follow 2,400 adults with lung cancer who are starting immunotherapy, comparing those who get clots with those who don't. The goal is to build a simple risk-prediction tool doctors can use to prevent clots and improve treatment safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTERIAL THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Chaoyang Hospital, Capital Medical University
RECRUITINGBeijing, China
-
Beijing Luhe Hospital, Capital Medical University
RECRUITINGBeijing, China
-
China-japan Friendship Hospital
RECRUITINGBeijing, China
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
-
The Fourth Hospital of Inner Mongolia Autonomous Region
RECRUITINGHohhot, Inner Mongolia, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection